创新通道与优先审批对检测节奏的影响

结论：通道加速的是审评，不是试验

进入创新或优先通道之后，常见的误解是整个注册流程都会变快。实际上加速的主要是审评排队和沟通环节，检测所需的物理时间一点没变。

老化要放那么久，耐久要跑那么多次，微生物培养要等那么多天。这些周期由试验本身决定，不因为产品进了加速通道就缩短。

结果就出现一种常见局面：审评侧已经准备好推进，企业这边的检测报告还没出来，加速通道的优势被自己抵消掉了。

检测环节的真实瓶颈

第四行和第五行是硬约束。 加速通道对它们无效，加钱也无效。所以做时间规划时，要先把这两类项目的周期固定下来，其余工作围绕它们排。

最后一行是不确定项，也是实际中最常导致计划落空的一项。整改需要多久，取决于问题出在哪里——参数调整可能一两天，结构改动可能一两个月。

申请通道之前就该做的事

加速通道的申请本身需要材料支撑，而其中一部分需要检测数据。所以检测的启动时点，应当在申请通道之前而不是之后。

建议在申请前完成这几项：产品性能的基本数据，用于支撑创新性或临床价值的论述；关键安全项目的摸底，确认不存在重大技术障碍；风险分析的初稿，其中识别的风险要有初步的验证思路。

没有这些数据，申请材料只能靠描述，说服力有限；有了数据，论述就落到实处。

并行准备的做法

进入通道后时间压力大，建议把工作拆成并行的几条线：

长周期试验先启动。 老化、耐久、微生物这类，排在最前面，不等其他项目。

短周期试验分批做。 按设备档期灵活安排，不必等长周期的结果。

资料编写与检测同步。 不要等报告全部出来再开始写资料，先按已知内容写框架，数据出来填进去。

整改预案提前想。 对风险较高的项目，事先想好如果不合格怎么改，这样真出问题时不必从头讨论。

加急的可行性与代价

检测加急不是无条件的。可行性取决于三点：设备有没有空档、方法本身能不能压缩、以及会不会影响其他在做的项目。

代价除了费用，还有两项容易被忽略：一是加急项目往往要打乱既有排期，实验室内部的协调成本会反映在价格上；二是压缩时间可能意味着减少冗余，比如原本计划测三个样品改成测两个，数据的稳健性会下降。

所以加急应当用在真正的关键路径上，而不是所有项目都加急。判断哪些在关键路径上，需要先把全部项目的周期排一遍。

与审评侧的沟通

加速通道通常伴随更密集的沟通机会。这些沟通里，检测相关的话题值得主动提出：

检测方案是否被认可、某个项目的方法选择是否合适、覆盖论证的思路是否成立。在检测开工之前把这些问清楚，比做完再被质疑要经济得多。

有些企业把沟通机会全用在临床和技术路线上，检测方案留到最后自己定。这是可惜的——检测方案的分歧同样会导致返工，而返工的周期不比其他环节短。

常见的节奏失误

一是等通道批准才启动检测。 申请到批准之间的时间被浪费掉，而这段时间足够跑完几个长周期项目。

二是按常规节奏排检测，指望后面追。 检测的长周期项目追不回来，前面省下的时间后面补不上。

三是样品准备不足，中途补件。 时间紧的时候补件的代价会被放大，因为排期插不进去。

四是整改预案缺失。 出问题才开始讨论怎么改，讨论本身就要花时间。

长周期项目的提前量怎么算

把不可压缩的项目单独拎出来算提前量，方法是从申报目标日倒推：报告编制需要几天、试验本身需要几周、样品准备需要几天、排期等待需要几天，逐项相加，得到最晚开工日。

算出来的日期往往比直觉早得多。 一个需要较长老化周期的项目，加上前后环节，最晚开工日可能在申报目标日的数月之前。这个结论如果不算一遍，很难凭感觉意识到。

算完之后，把这些最晚开工日标在项目计划上，作为硬节点管理。其他工作可以调整，这些不能。

通道内的变更处理

进了加速通道之后如果产品还要改，处理会比常规情况更被动：时间窗口紧，重新验证的余地小。

所以进通道前应当把产品设计冻结，至少把影响安全有效性的部分冻结。带着未定的设计进通道，等于把风险留在了最没有时间应对的阶段。

如果确实必须变更，要立即评估对已完成检测的影响，判断哪些数据还能用、哪些要重做，并尽快与审评侧沟通时间安排。

我们的做法

承接加速通道项目时，我们会先把项目清单按周期长短排序，把不可压缩的项目标出来，和委托方一起确定开工顺序。这张按周期排序的清单，往往比按标准章节排的清单更有用——它直接告诉你什么必须今天开始。

对于时间特别紧的项目，我们会在报价阶段就说明哪些能加急、哪些不能，以及加急的具体代价。把话说在前面，比事后解释为什么某一项压不下来要好。

如果你的产品准备申请加速通道，或者已经进了通道但检测节奏没理顺，可以把项目清单和时间节点发过来一起排，或者直接联系：132 4819 8029。能力范围见服务介绍，流程与周期见检测流程，其他问题见常见问题。

English version

Conclusion. A common misunderstanding about innovation and priority review pathways is that the whole registration process speeds up. What actually accelerates is review queuing and communication. The physical time required for testing does not change: ageing takes as long as it takes, endurance runs the same number of cycles, microbiological culture needs the same number of days. The result is a familiar situation in which the review side is ready to proceed while the manufacturer's test reports are still outstanding, cancelling out the advantage of the pathway.

Where the real bottlenecks are. Equipment queuing can be compressed through advance booking or expediting. Sample preparation can be compressed through planning and preparing extra units. Test execution can be partly compressed by running items in parallel, subject to equipment availability. Ageing and endurance essentially cannot be compressed, because the duration is set by the method. Microbiological culture cannot be compressed, because it is a biological process. Report preparation and review can be expedited. Remediation and retesting are uncertain, depending on the nature of the problem.

The ageing and microbiological items are hard constraints, unaffected by the pathway and unaffected by money. Fix those durations first and arrange everything else around them. Remediation is the item that most often derails a plan: a parameter adjustment may take a day or two, a structural change a month or two.

What to do before applying to the pathway. The application itself needs supporting material, part of which requires test data, so testing should start before the application rather than after. Complete basic performance data to support the innovation or clinical value argument, preliminary testing of key safety items to confirm there is no major technical obstacle, and a draft risk analysis in which identified risks have a preliminary verification approach. Without data the application rests on description alone.

Working in parallel. Start long-duration tests first, ahead of everything else. Run short-duration items in batches as equipment allows, without waiting for long-duration results. Write the dossier alongside testing rather than after it, building the framework and filling in data as it arrives. And think through remediation options in advance for higher-risk items, so that a failure does not begin with a discussion from first principles.

Expediting: feasibility and cost. Whether testing can be expedited depends on equipment availability, whether the method itself can be shortened, and the effect on other work in progress. Beyond price, two costs are easily overlooked. Expedited work disrupts existing scheduling, and that internal coordination cost is reflected in the price. And compressing time may mean reducing redundancy, such as testing two samples instead of three, which weakens the robustness of the data. Expediting should therefore be applied to the genuine critical path rather than to everything, which requires mapping all durations first.

Communication with the review side. Accelerated pathways usually come with more frequent communication opportunities, and testing topics are worth raising in them: whether the test plan is acceptable, whether a particular method choice is appropriate, whether the coverage argument holds. Settling these before testing starts is far cheaper than being challenged afterwards. Some manufacturers use every communication opportunity on clinical and technical strategy and settle the test plan alone at the end, which is a missed opportunity, since disagreements about testing cause rework on a comparable timescale.

Common scheduling errors. Waiting for pathway approval before starting testing, wasting a period long enough to complete several long-duration items. Scheduling testing at a normal pace and expecting to catch up later, which long-duration items do not permit. Preparing insufficient samples and needing a resupply, whose cost is magnified when schedules are tight. And lacking a remediation plan, so that discussion begins only once a problem appears.

How we handle it. For accelerated-pathway work we sort the item list by duration and mark the incompressible items, then agree the starting order with the client. A list sorted by duration is often more useful than one sorted by standard clause, because it says directly what must begin today. Where time is very tight we state at the quotation stage which items can be expedited, which cannot, and at what cost.

Send us the item list and your milestone dates and we will sequence it. Phone or WeChat: +86 132 4819 8029.